Safety Study of Nebivolol for COPD Patients
- Registration Number
- NCT01939990
- Lead Sponsor
- University of Chicago
- Brief Summary
The purpose of this study is to demonstrate the safety and effectiveness of the study drug Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary Disease (COPD).
- Detailed Description
The study would be a randomized, placebo-controlled trial of 60 hypertensive patients with documented COPD greater than age 40.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Clinical diagnosis of high blood pressure and chronic obstructive pulmonary disease (COPD)
Exclusion Criteria
- Asthma; Heart failur;
- End stage kidney disease;
- acute myocardial infarction,unstable angina, stroke or TIA within the past year;
- Females who are pregnant, lactating or women of childbearing potential who are not using approved method of contraception.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nebivolol Nebivolol Group A will be given Nebivolol 5 to 10mg per day Placebo Placebo Group B will be given Placebo.
- Primary Outcome Measures
Name Time Method to assess blood pressure control baseline to 4 weeks blood pressure control will be assessed per collection of research data at protocol visits.
- Secondary Outcome Measures
Name Time Method to assess pulmonary function tests baseline to 4 weeks pulmonary function tests will be assessed at protocol visits
Trial Locations
- Locations (1)
University of Chicago Medical Center
馃嚭馃嚫Chicago, Illinois, United States